Pasar al contenido principal

REACCIONES MULTICOMPONENTE: DESCUBRIMIENTO, DEASARROLLO Y APLICACIONES EN BIOMEDICINA

PID2019-107991RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Insights into the pharmacokinetics and in vitro cell-based studies of the imidazoline I2 receptor ligand B06

  • Bagán Polonio, Andrea
  • Morales García, José A.
  • Griñán Ferré, Christian
  • Díaz Navarro, Caridad
  • Pérez del Palacio, José
  • Ramos Martín, Maria Carmen
  • Vicente Pérez, Francisca
  • Pérez Fernández, Belén
  • Brea Floriani, José Manuel
  • Loza García, María Isabel
  • Pallàs Lliberia, Mercè
  • Escolano Mirón, Carmen
The impact of neurodegenerative diseases (ND) is becoming unbearable for humankind due to their vast prevalence and the lack of efficacious treatments. In this scenario, we focused on imidazoline I2 receptors (I2-IR) that are widely distributed in the brain and are altered in patients with brain disorders. We took the challenge of modulating I2-IR by developing structurally new molecules, in particular, a family of bicyclic α-iminophosphonates, endowed with high affinity and selectivity to these receptors. Treatment of two murine models, one for age-related cognitive decline and the other for Alzheimer’s disease (AD), with representative compound B06 ameliorated their cognitive impairment and improved their behavioural condition. Furthermore, B06 revealed beneficial in vitro ADME-Tox properties. The pharmacokinetics (PK) and metabolic profile are reported to de-risk B06 for progressing in the preclinical development. To further characterize the pharmacological properties of B06, we assessed its neuroprotective properties and beneficial effect in an in vitro model of Parkinson’s disease (PD). B06 rescued the human dopaminergic cell line SH-SY5Y from death after treatment with 6-hydroxydopamine (6-OHDA) and showed a crucial anti-inflammatory effect in a cellular model of neuroinflammation. This research reveals B06 as a putative candidate for advancing in the difficult path of drug discovery and supports the modulation of I2-IR as a fresh approach for the therapy of ND
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease

  • Rodríguez Arévalo, Sergio
  • Bagán, Andrea
  • Griñán Ferré, Christian
  • Vasilopoulou, Foteini
  • Pallàs, Mercè
  • Brocos Mosquera, Iria
  • Callado, Luis F.
  • Loza García, María Isabel
  • Martínez Rodríguez, Antón Leandro
  • Brea Floriani, José Manuel
  • Pérez, Belén
  • Molins, Elies
  • De Jonghe, Steven
  • Daelemans, Dirk
  • Radan, Milica
  • Djikic, Teodora
  • Nikolic, Katarina
  • Hernández Hernández, Elena
  • García Fuster, M. Julia
  • García Sevilla, Jesús A.
  • Escolano, Carmen
Recent findings unveil the pharmacological modulation of imidazoline I2 receptors (I2-IR) as a novel strategy to face unmet medical neurodegenerative diseases. In this work, we report the chemical characterization, three-dimensional quantitative structure-activity relationship (3D-QSAR) and ADMET in silico of a family of benzofuranyl-2-imidazoles that exhibit affinity against human brain I2-IR and most of them have been predicted to be brain permeable. Acute treatment in mice with 2-(2-benzofuranyl)-2-imidazole, known as LSL60101 (garsevil), showed non-warning properties in the ADMET studies and an optimal pharmacokinetic profile. Moreover, LSL60101 induced hypothermia in mice while decreased pro-apoptotic FADD protein in the hippocampus. In vivo studies in the familial Alzheimer's disease 5xFAD murine model with the representative compound, revealed significant decreases in the protein expression levels of antioxidant enzymes superoxide dismutase and glutathione peroxidase in hippocampus. Overall, LSL60101 plays a neuroprotective role by reducing apoptosis and modulating oxidative stress
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Fluorizoline-induced apoptosis requires prohibitins in nematodes and human cells

  • Saura-Esteller, José
  • Sánchez-Vera, Ismael
  • Núñez-Vázquez, Sonia
  • Jabalquinto-Carrasco, Judith
  • Cosialls, Ana M.
  • Mendive-Tapia, Lorena
  • Kukhtar, Dmytro
  • Martínez-Bueno, Manuel
  • Lavilla, Rodolfo
  • Cerón, Julián
  • Artal-Sanz, Marta
  • Pons, Gabriel
  • Iglesias-Serret, Daniel
  • Gil, Joan
We previously showed that fluorizoline, a fluorinated thiazoline compound, binds to both subunits of the mitochondrial prohibitin (PHB) complex, PHB1 and PHB2, being the expression of these proteins required for fluorizoline-induced apoptosis in mouse embryonic fibroblasts. To investigate the conservation of this apoptotic mechanism, we studied the effect of PHB downregulation on fluorizoline activity on two human cell lines, HEK293T and U2OS. Then, we asked whether PHBs mediate the effect of fluorizoline in a multicellular organism. Interestingly, reduced levels of PHBs in the human cells impaired the induction of apoptosis by fluorizoline. We observed that fluorizoline has a detrimental dose-dependent effect on the development and survival of the nematode model Caenorhabditis elegans. Besides, such effects of fluorizoline treatment in living nematodes were absent in PHB mutants. Finally, we further explored the apoptotic pathway triggered by fluorizoline in human cell lines. We found that the BH3-only proteins NOXA, BIM and PUMA participate in fluorizoline-induced apoptosis and that the induction of NOXA and PUMA is dependent on PHB expression., This work was supported by grants from the Agencia Estatal de Investigación (Ministerio de Ciencia e Innovación), European Regional Development Fund (ERDF), the European Research Council, the Junta de Andalucía and the Instituto de Salud Carlos III (ISCIII) (SAF2017-83178-R to J.G.; PID2019-107991RB-I00 to R.L.; ERC-2011-StG-281691 and C2A ID: 42571/Exp: 70806 to M.A-S; PI15-00895 to J.C.). J.S-E and I.S-V are recipients of research fellowships from the Ministerio de Ciencia e Innovación. S.N-V is recipient of a research fellowship from Universitat de Barcelona. MD.M-B was supported by the Plan de Empleo Juvenil (EJP09) from the Junta de Anadalucía. D.K has a FI AGAUR fellowship from Generalitat de Catalunya.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease

  • Rodriguez Arévalo, Sergio
  • Bagán, Andrea
  • Griñán-Ferré, Christian
  • Vasilopoulou, Foteini
  • Pallàs, Mercè
  • Brocos Mosquera, Iria
  • Callado, Luis F.
  • Loza, M Isabel
  • Martínez, Antón L.
  • Brea, José Manuel
  • Pérez, Belén
  • Molins, Elies
  • De Jonghe, Steven
  • Daelemans, Dirk
  • Radan, Milica
  • Djikic, Teodora
  • Nikolic, Katarina
  • Hernández Hernández, Elena
  • García-Fuster, M. Julia
  • García Sevilla, Jesús A.
  • Escolano, Carmen
Recent findings unveil the pharmacological modulation of imidazoline I2 receptors (I2-IR) as a novel strategy to face unmet medical neurodegenerative diseases. In this work, we report the chemical characterization, three-dimensional quantitative structure-activity relationship (3D-QSAR) and ADMET in silico of a family of benzofuranyl-2-imidazoles that exhibit affinity against human brain I2-IR and most of them have been predicted to be brain permeable. Acute treatment in mice with 2-(2-benzofuranyl)-2-imidazole, known as LSL60101 (garsevil), showed non-warning properties in the ADMET studies and an optimal pharmacokinetic profile. Moreover, LSL60101 induced hypothermia in mice while decreased pro-apoptotic FADD protein in the hippocampus. In vivo studies in the familial Alzheimer's disease 5xFAD murine model with the representative compound, revealed significant decreases in the protein expression levels of antioxidant enzymes superoxide dismutase and glutathione peroxidase in hippocampus. Overall, LSL60101 plays a neuroprotective role by reducing apoptosis and modulating oxidative stress., This work was supported by Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación (Spain, PID2019-107991RB-I00, PID2019-106285RB), the Basque Government (IT1211/19) and Generalitat de Catalunya (GC) (2017SGR106). The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434) under agreement CI18-00002. This activity has received funding from the European Institute of Innovation and Technology (EIT). This body of the European Union receives support from the European Union's Horizon 2020 research and innovation programme. C.G.-F, F.V., C.E., S.R.-A., A.B., and M.P. Financial support was provided for F.V. (University of Barcelona, APIF_2017), S.R.-A. (Generalitat de Catalunya, 2018FI_B_00227), A.B. (Institute of Biomedicine UB_2018), J.A.G.-S. is a member emeritus of the Institut d’Estudis Catalans (Barcelona, Catalonia). E.H.-H. is supported by a predoctoral scholarship (FPI/2102/2018; Consejería de Innovación, Investigación y Turismo del Gobierno de las Islas Baleares y del Fondo Social Europeo). M.R., T.D., and K.N. kindly acknowledge the project funded by the Ministry of Science and Technological Development of the Republic of Serbia, Contract No. 451-03-68/2020-14/200161, and HORISON 2020-COST-Action CA18133 ERNEST: European Research Network on Signal Transduction. E. M. acknowledges funding to Severo Ochoa: CEX2019-917S. M.I.L, A.L.M. and J.B. gratefully acknowledge support from Xunta de Galicia (ED431C 2018/21 and ED431G 2019/02) and European Regional Development Fund (ERDF)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

A new family of subnanomolar inhibitors of soluble epoxide hydrolase

  • Escolano, Carmen
  • Bagán, Andrea
  • Turcu, Andreea L.
  • Morisseau, Christophe
  • Loza, María Isabel
  • Brea, José Manuel
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Vázquez, Santiago
Trabajo presentado en el ASPET Annual Meeting at Experimental Biology 2022, celebrado en Philadelphia, PA (Estados Unidos), del 2 al 5 de abril de 2022, Epoxyeicosatrienoic acids (EETs) are endogenous chemical mediators derived from arachidonic acid that show anti-inflammatory, antihypertensive, analgesic, angiogenic, and antiatherosclerotic effects. Soluble epoxide hydrolase (sEH) converts EETs to the corresponding dihydroxyeicosatrienoic acids (DHETs), whereby the biological effects of EETs are diminished, eliminated, or altered.1 Therefore, inhibition of sEH has been suggested as a novel pharmacological approach for the treatment of pain-related disorders and various inflammatory diseases, and a few sEH inhibitors (sEHI) have reached clinical trials, This research was funded by Grants PID2020-118127RB-I00 and PID2019-107991RB-I00 funded by MCIN/AEI/ 10.13039/501100011033 and by “ERDF A way of making Europe” to S.V. and C.E. Financial support from Generalitat de Catalunya (2017 SGR106) and Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), to S.V., and from the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21) to M.I.L. are acknowledged. Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01DK103616 to B.D.H.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sex differences in the antidepressant-like response and molecular events induced by the imidazoline-2 receptor agonist CR4056 in rats

  • Hernández Hernández, Elena
  • Ledesma-Corvi, S.
  • Yáñez-Gómez, Fernando
  • Garau, C.
  • Gálvez-Melero, Laura
  • Bagán, Andrea
  • Escolano, Carmen
  • García-Fuster, M. Julia
In searching for novel targets to design antidepressants, among the characterized imidazoline receptors (IR), I2 receptors are an innovative therapeutical approach since they are dysregulated in major depressive disorder and by classical antidepressant treatments. In fact, several I2 agonists have been characterized for their antidepressant-like potential, but the results in terms of efficacy were mixed and exclusively reported in male rodents. Since there are well-known sex differences in antidepressant-like efficacy, this study characterized the potential effects induced by two I2 drugs, CR4056 (i.e., most promising drug already in phase II clinical trial for its analgesic properties) and B06 (a compound from a new family of bicyclic α-iminophosphonates) under the stress of the forced-swim test in male and female rats exposed to early-life stress. Moreover, some hippocampal neuroplasticity markers related to the potential effects observed were also evaluated (i.e., FADD, p-ERK/ERK, mBDNF, cell proliferation: Ki-67 + cells). The main results replicated the only prior study reporting the efficacy of CR4056 in male rats, while providing new data on its efficacy in females, which was clearly dependent on prior early-life stress exposure. Moreover, B06 showed no antidepressant-like effects in male or female rats. Finally, CR4056 increased FADD content and decreased cell proliferation in hippocampus, without affecting p-ERK/t-ERK ratio and/or mBDNF content. Interestingly, these effects were exclusively observed in female rats, and independently of early-life conditions, suggesting some distinctive molecular underpinnings participating in the therapeutic response of CR4056 for both sexes. In conjunction, these results present CR4056 with an antidepressant-like potential, especially in female rats exposed to stress early in life, together with some neuronal correlates described in the context of these behavioral changes in females., This research was partly supported by several grants to MJG-F: PID2020-118582RB-I00 (MCIN/AEI/10.13039/501100011033) and PDR2020/14 (Comunitat Autonoma ` de les Illes Balears through the Direccio ´ General de Política Universitaria ` i Recerca with funds from the Tourist Stay Tax Law ITS 2017–006). Moreover, this study was also funded by PID2019-107991RB-I00 (MCIN/AEI) and PDC2022-133441- I00 (MCIN/AEI/10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR”) to CE. These entities had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The salaries of personnel were covered by several research programs: predoctoral scholarships to EH-H (FPI/2102/2018) from Consejería de Innovacion, ´ Investigacion ´ y Turismo del Gobierno de las Islas Baleares y del Fondo Social Europeo, who is currently funded by the Margarita Salas Program (Ministerio de Universidades; Plan de Recuperacion, ´ Transformacion ´ y Resilencia; NextGenerationEU) with the participation of the University of the Balearic Islands; JUNIOR Program to SL-C from “TALENT PLUS Construint Salut, Generant Valor” (IdISBa, GOIB); CG is funded by the María Zambrano Program (Ministerio de Universidades; Plan de Recuperacion, ´ Transformacion ´ y Resilencia; NextGenerationEU) at the University of the Balearic Islands; AB received financial support from Institute of Biomedicine UB_2018.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exploring the reactivity of bicyclic α-iminophosphonates to access new imidazoline I<inf>2</inf> receptor ligands

  • Bagán, Andrea
  • Abás, Sònia
  • Palà Pujadas, Judith
  • Irisarri, Alba
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Muneta Arrate, Itziar
  • Muguruza, Carolina
  • Callado, Luis F.
  • Pérez, Belén
  • Molins, Elies
  • Morales García, José
  • Escolano, Carmen
Recent studies pointed out the modulation of imidazoline I2 receptors (I2-IR) by selective ligands as a putative strategy to face neurodegenerative diseases. Foregoing the classical 2-imidazoline/imidazole-containing I2-IR ligands, we report a family of bicyclic α-iminophosphonates endowed with high affinity and selectivity upon I2-IR and we advanced a representative compound B06 in preclinical phases. In this paper, we describe the synthetic possibilities of bicyclic α-iminophosphonates by exploring its ambivalent reactivity, leading to unprecedented molecules that showed promising activities as I2-IR ligands in human brain tissues and good BBB permeation capabilities. After in silico ADME prediction studies, we assessed the neuroprotective properties of selected compounds and beneficial effect in an in vitro model of Alzheimeŕs and Parkinson's disease. Along with their neuroprotective effect, compounds showed a potent anti-inflammatory response when evaluated in a neuroinflammation cellular model. Moreover, this is the first time that the neuroprotective effects of imidazoline I2-IR ligands in a transgenic Alzheimer's disease Caenorhabditis elegans strain are investigated. Using a thrashing assay, we found a significant cognition improvement in this in vivo model after treatment with the new bicyclic α-phosphoprolines. Therefore, our results confirmed the need of exploring structurally new I2-IR ligands and their potential for therapeutic strategies in neurodegeneration., This work was supported by Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación (Spain, PID2019-107991RB-I00, PID2022-1380790B-I00), Basque Government (IT-1211-19 and 1512-22), Generalitat de Catalunya (GC) (2021 SGR 00357) and PDC2022-133441-I00 (MCIN/AEI/ 10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR) and by UCM-Santander (PR44/21-29931 to J.A.M.-G.). The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434) under agreement CI18-00002. This activity has received funding from the European Institute of Innovation and Technology (EIT). This body of the European Union receives support from the European Union’s Horizon 2020 research and innovation programme., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S)., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer’s Disease

  • Bagán, Andrea
  • Morales García, José Ángel
  • Escolano, Carmen
Humanity is facing a vast prevalence of neurodegenerative diseases, with Alzheimer’s disease (AD) being the most dominant, without efficacious drugs, and with only a few therapeutic targets identified. In this scenario, we aim to find molecular entities that modulate imidazoline I2 receptors (I2-IRs) that have been pointed out as relevant targets in AD. In this work, we explored structural modifications of well-established I2-IR ligands, giving access to derivatives with an imidazole-linked heterocycle as a common key feature. We report the synthesis, the affinity in human I2-IRs, the brain penetration capabilities, the in silico ADMET studies, and the three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of this new bunch of I2-IR ligands. Selected compounds showed neuroprotective properties and beneficial effects in an in vitro model of Parkinson’s disease, rescued the human dopaminergic cell line SH-SY5Y from death after treatment with 6-hydroxydopamine, and showed crucial anti-inflammatory effects in a cellular model of neuroinflammation. After a preliminary pharmacokinetic study, we explored the action of our representative 2-(benzo[b]thiophen-2-yl)-1H-imidazole LSL33 in a mouse model of AD (5xFAD). Oral administration of LSL33 at 2 mg/Kg for 4 weeks ameliorated 5XFAD cognitive impairment and synaptic plasticity, as well as reduced neuroinflammation markers. In summary, this new I2-IR ligand that promoted beneficial effects in a well-established AD mouse model should be considered a promising therapeutic strategy for neurodegeneration.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Insights into the Pharmacokinetics and In Vitro Cell-Based Studies of the Imidazoline I2 Receptor Ligand B06

  • Bagán, Andrea
  • Morales-García, José A.|||0000-0001-9008-0056
  • Griñán-Ferré, Christian|||0000-0002-5424-9130
  • Díaz Navarro, Caridad|||0000-0003-1240-0143
  • Del Palacio, José Pérez|||0000-0001-8918-6873
  • Ramos, Maria Carmen|||0000-0002-3674-615X
  • Vicente Pérez, Francisca|||0000-0003-3198-9205
  • Pérez, Belén|||0000-0001-5801-1704
  • Brea, José|||0000-0002-5523-1979
  • Loza, María Isabel|||0000-0003-4730-0863
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Escolano, Carmen|||0000-0002-9117-8239
The impact of neurodegenerative diseases (ND) is becoming unbearable for humankind due to their vast prevalence and the lack of efficacious treatments. In this scenario, we focused on imidazoline I2 receptors (I2-IR) that are widely distributed in the brain and are altered in patients with brain disorders. We took the challenge of modulating I2-IR by developing structurally new molecules, in particular, a family of bicyclic α-iminophosphonates, endowed with high affinity and selectivity to these receptors. Treatment of two murine models, one for age-related cognitive decline and the other for Alzheimer's disease (AD), with representative compound B06 ameliorated their cognitive impairment and improved their behavioural condition. Furthermore, B06 revealed beneficial in vitro ADME-Tox properties. The pharmacokinetics (PK) and metabolic profile are reported to de-risk B06 for progressing in the preclinical development. To further characterize the pharmacological properties of B06, we assessed its neuroprotective properties and beneficial effect in an in vitro model of Parkinson's disease (PD). B06 rescued the human dopaminergic cell line SH-SY5Y from death after treatment with 6-hydroxydopamine (6-OHDA) and showed a crucial anti-inflam-matory effect in a cellular model of neuroinflammation. This research reveals B06 as a putative candidate for advancing in the difficult path of drug discovery and supports the modulation of I2-IR as a fresh approach for the therapy of ND.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer's Disease

  • Bagán, Andrea
  • Rodriguez-Arévalo, Sergio
  • Taboada-Jara, Teresa
  • Griñán-Ferré, Christian|||0000-0002-5424-9130
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Brocos Mosquera, Iria|||0000-0002-6471-4892
  • Callado, Luis F.|||0000-0001-9941-012X
  • Morales-García, José A.|||0000-0001-9008-0056
  • Pérez, Belén|||0000-0001-5801-1704
  • Díaz Navarro, Caridad|||0000-0003-1240-0143
  • Fernández-Godino, Rosario
  • Genilloud, Olga
  • Beljkas, Milan
  • Oljacic, Slavica
  • Nikolic, Katarina
  • Escolano, Carmen|||0000-0002-9117-8239
Humanity is facing a vast prevalence of neurodegenerative diseases, with Alzheimer's disease (AD) being the most dominant, without efficacious drugs, and with only a few therapeutic targets identified. In this scenario, we aim to find molecular entities that modulate imidazoline I2 receptors (I2-IRs) that have been pointed out as relevant targets in AD. In this work, we explored structural modifications of well-established I2-IR ligands, giving access to derivatives with an imidazole-linked heterocycle as a common key feature. We report the synthesis, the affinity in human I2-IRs, the brain penetration capabilities, the in silico ADMET studies, and the three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of this new bunch of I2-IR ligands. Selected compounds showed neuroprotective properties and beneficial effects in an in vitro model of Parkinson's disease, rescued the human dopaminergic cell line SH-SY5Y from death after treatment with 6-hydroxydopamine, and showed crucial anti-inflammatory effects in a cellular model of neuroinflammation. After a preliminary pharmacokinetic study, we explored the action of our representative 2-(benzo[b]thiophen-2-yl)-1H-imidazole LSL33 in a mouse model of AD (5xFAD). Oral administration of LSL33 at 2 mg/Kg for 4 weeks ameliorated 5XFAD cognitive impairment and synaptic plasticity, as well as reduced neuroinflammation markers. In summary, this new I2-IR ligand that promoted beneficial effects in a well-established AD mouse model should be considered a promising therapeutic strategy for neurodegeneration.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

An Imidazoline 2 Receptor Ligand Relaxes Mouse Aorta via Off-Target Mechanisms Resistant to Aging

  • Jiménez Altayó, Francesc|||0000-0002-9034-2041
  • Cabrera, Anna
  • Bagán, Andrea
  • Gimenez-Llort, Lydia|||0000-0002-4091-489X
  • D'Ocon, Pilar|||0000-0001-8544-7124
  • Pérez, Belén|||0000-0001-5801-1704
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Escolano, Carmen|||0000-0002-9117-8239
Imidazoline receptors (IR) are classified into three receptor subtypes (IR, IR, and IR) and previous studies showed that regulation of IR signaling has neuroprotective potential. In order to know if IR has a role in modulating vascular tone in health and disease, we evaluated the putative vasoactive effects of two recently synthesized IR ligands, diethyl (1RS,3aSR,6aSR)-5-(3-chloro-4-fluorophenyl)-4,6-dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole -1-phosphonate (B06) and diethyl [(1-(3-chloro-4-fluorobenzyl)-5,5-dimethyl-4-phenyl-4,5-dihydro-1H-imidazol-4-yl]phosphonate] (MCR5). Thoracic aortas from Oncins France 1 (3- to 4-months-old) and C57BL/6 (3- to 4- and 16- to 17-months-old mice) were mounted in tissue baths to measure isometric tension. In young mice of both strains, MCR5 induced greater relaxations than either B06 or the high-affinity IR selective ligand 2-(2-benzofuranyl)-2-imidazoline (2-BFI), which evoked marginal responses. MCR5 relaxations were independent of IR, as IR ligands did not significantly affect them, involved activation of smooth muscle K channels and inhibition of L-type voltage-gated Ca 2+ channels, and were only slightly modulated by endothelium-derived nitric oxide (negatively) and prostacyclin (positively). Notably, despite the presence of endothelial dysfunction in old mice, MCR5 relaxations were preserved. In conclusion, the present study provides evidence against a functional contribution of IR in the modulation of vascular tone in the mouse aorta. Moreover, the IR ligand MCR5 is an endothelium-independent vasodilator that acts largely via IR-independent pathways and is resistant to aging. We propose MCR5 as a candidate drug for the management of vascular disease in the elderly.